Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
- C. Geyer, J. Forster, +15 authors D. Cameron
- The New England journal of medicine
- 28 December 2006
Lapatinib plus capecitabine is superior to cape citabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab. Expand
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
It is reported that concentration-dependent antiproliferative effects of lapatinib were seen in all breast cancer cell lines tested but varied significantly between individual cell lines with up to 1,000-fold difference in the IC(50)s (range, 0.010-18.6 micromol/L). Expand
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
- H. Gómez, D. Doval, +11 authors G. Sledge
- Journal of clinical oncology : official journal…
- 20 June 2008
Lapatinib demonstrated clinical activity and was well tolerated as first-line therapy in ErbB2-amplified locally advanced or metastatic breast cancer and supports further evaluation of lapatinib in first- line and early-stage Erb B2-overexpressing breast cancer. Expand
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.
Results show that an immunoconjugate targeted to CD33 can selectively ablate malignant hematopoiesis in some patients with AML. Expand
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence
In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg®), an antibody‐targeted chemotherapy for CD33‐positive acute myeloid leukemia (AML).
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.
Expression of multidrug resistance (MDR) features by acute myeloid leukemia (AML) cells predicts a poor response to many treatments. The MDR phenotype often correlates with expression of… Expand
A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
The small-molecule pan-Bcl-2 inhibitor obatoclax mesylate is well tolerated and these results support its further investigation in patients with leukemia and myelodysplasia. Expand
Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA.
Tumor-specific amplification of the gene encoding cyclin-dependent kinase 6 (CDK6) is found and this data implicate the CDK6 gene in genomic amplification and illustrate the potential of RLGS for the more general identification and cloning of novel genes that are amplified in human cancer. Expand
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.
- V. V. D. van der Velden, J. T. te Marvelde, +4 authors J. V. van Dongen
- Biology, Medicine
- 15 May 2001
Data indicate that Mylotarg is rapidly and specifically targeted to CD33(+) cells, followed by internalization and subsequent induction of cell death, which is a promising therapy in patients with acute myeloid leukemia. Expand
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
Gemtuzumab ozogamicin was relatively well tolerated at 6 mg/m2 for 2 doses and was equally effective in patients with refractory and relapsed disease, and in combination with standard induction therapy for childhood AML. Expand